DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 165.65 Million USD | -32.8% |
| 2022 | 246.5 Million USD | 68.0% |
| 2021 | 146.72 Million USD | -46.11% |
| 2020 | 272.24 Million EUR | 0.65% |
| 2019 | 270.49 Million EUR | 37.68% |
| 2018 | 196.46 Million EUR | -7.9% |
| 2017 | 213.31 Million EUR | -29.45% |
| 2016 | 302.36 Million EUR | -19.44% |
| 2015 | 375.3 Million EUR | 146.09% |
| 2014 | 152.5 Million EUR | 138.87% |
| 2013 | 63.84 Million EUR | 12.34% |
| 2012 | 56.83 Million EUR | 178.93% |
| 2011 | 20.37 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 114.19 Million EUR | -15.84% |
| 2024 Q1 | 145.89 Million USD | -20.27% |
| 2023 Q2 | 217.51 Million USD | -6.62% |
| 2023 Q1 | 232.92 Million USD | -5.51% |
| 2023 FY | 165.65 Million USD | -32.8% |
| 2023 Q4 | 182.98 Million USD | 1265.52% |
| 2023 Q3 | -15.7 Million USD | -107.22% |
| 2022 FY | 246.5 Million USD | 68.0% |
| 2022 Q4 | 246.51 Million USD | -0.64% |
| 2022 Q1 | 117.58 Million USD | -19.86% |
| 2022 Q2 | 284.97 Million USD | 142.37% |
| 2022 Q3 | 248.11 Million USD | -12.93% |
| 2021 Q2 | 200.58 Million USD | -9.4% |
| 2021 Q1 | 221.4 Million USD | -18.67% |
| 2021 Q3 | 170.92 Million USD | -14.79% |
| 2021 Q4 | 146.72 Million USD | -14.16% |
| 2021 FY | 146.72 Million USD | -46.11% |
| 2020 Q4 | 272.24 Million EUR | 0.0% |
| 2020 Q2 | 337.01 Million EUR | 0.0% |
| 2020 FY | 272.24 Million EUR | 0.65% |
| 2019 Q4 | 270.49 Million EUR | 60.24% |
| 2019 Q2 | 212.23 Million EUR | 0.0% |
| 2019 Q3 | 168.8 Million EUR | -20.46% |
| 2019 FY | 270.49 Million EUR | 37.68% |
| 2018 FY | 196.46 Million EUR | -7.9% |
| 2018 Q4 | 196.46 Million EUR | 0.0% |
| 2018 Q2 | 289.36 Million EUR | 0.0% |
| 2017 Q2 | 272.15 Million EUR | 0.0% |
| 2017 Q4 | 213.31 Million EUR | 0.0% |
| 2017 FY | 213.31 Million EUR | -29.45% |
| 2016 Q4 | 302.36 Million EUR | 0.0% |
| 2016 FY | 302.36 Million EUR | -19.44% |
| 2016 Q2 | 364.91 Million EUR | 0.0% |
| 2015 Q4 | 375.3 Million EUR | 0.0% |
| 2015 Q2 | 133.47 Million EUR | 0.0% |
| 2015 FY | 375.3 Million EUR | 146.09% |
| 2014 Q2 | 52.93 Million EUR | 0.0% |
| 2014 Q4 | 152.5 Million EUR | 0.0% |
| 2014 FY | 152.5 Million EUR | 138.87% |
| 2013 FY | 63.84 Million EUR | 12.34% |
| 2013 Q4 | 63.84 Million EUR | 0.0% |
| 2013 Q2 | 50.45 Million EUR | 0.0% |
| 2012 Q4 | 56.83 Million EUR | 0.0% |
| 2012 FY | 56.83 Million EUR | 178.93% |
| 2012 Q2 | 60.03 Million EUR | 0.0% |
| 2011 Q4 | 20.37 Million EUR | 0.0% |
| 2011 FY | 20.37 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -1026.109% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 49.352% |
| Adocia SA | 24.95 Million EUR | -563.771% |
| Aelis Farma SA | 26.28 Million EUR | -530.306% |
| Biophytis S.A. | 11.93 Million EUR | -1287.824% |
| Advicenne S.A. | 12.4 Million EUR | -1235.139% |
| genOway Société anonyme | 31.84 Million EUR | -420.221% |
| IntegraGen SA | 8 Million EUR | -1970.542% |
| Medesis Pharma S.A. | 1.92 Million EUR | -8499.265% |
| Neovacs S.A. | 47.53 Million EUR | -248.492% |
| NFL Biosciences SA | 3.97 Million EUR | -4071.901% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -1010.786% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -4321.158% |
| Sensorion SA | 46.49 Million EUR | -256.283% |
| Theranexus Société Anonyme | 7.23 Million EUR | -2188.708% |
| TME Pharma N.V. | 2.49 Million EUR | -6549.966% |
| Valbiotis SA | 33.24 Million EUR | -398.227% |
| TheraVet SA | 7.53 Million EUR | -2098.653% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -369.611% |
| argenx SE | 4.11 Billion EUR | 95.972% |
| BioSenic S.A. | 9.55 Million EUR | -1632.929% |
| Celyad Oncology SA | 16.28 Million EUR | -917.385% |
| Galapagos NV | 4.35 Billion EUR | 96.198% |
| Genfit S.A. | 173.87 Million EUR | 4.728% |
| GeNeuro SA | 6.31 Million EUR | -2524.003% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -247.414% |
| Innate Pharma S.A. | 184.19 Million EUR | 10.067% |
| Inventiva S.A. | 69.13 Million EUR | -139.591% |
| MaaT Pharma SA | 42.93 Million EUR | -285.853% |
| MedinCell S.A. | 36.94 Million EUR | -348.335% |
| Nanobiotix S.A. | 93.89 Million EUR | -76.417% |
| Onward Medical N.V. | 43.62 Million EUR | -279.68% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -54.958% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -102.26% |
| Oxurion NV | 6.55 Million EUR | -2429.018% |
| Pharming Group N.V. | 426.33 Million EUR | 61.146% |
| Poxel S.A. | 4.82 Million EUR | -3334.598% |
| GenSight Biologics S.A. | 9.08 Million EUR | -1722.941% |
| Transgene SA | 45.21 Million EUR | -266.346% |
| Financière de Tubize SA | 1.92 Billion EUR | 91.373% |
| UCB SA | 15.53 Billion EUR | 98.934% |
| Valneva SE | 469.39 Million EUR | 64.709% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -437.321% |